13
|
Walter-Croneck A, Grzasko N, Soroka-Wojtaszko M, Jurczyszyn A, Torosian T, Rymko M, Nowicki A, Druzd-Sitek A, Lech-Maranda E, Madro E, Zielinska P, Grygoruk-Wisniowska I, Blonska D, Usnarska-Zubkiewicz L, Potoczek S, Iskierka E, Masternak A, Holojda J, Dawidowska D, Gawron L, Barchnicka A, Olszewska-Szopa M, Rybicka M, Gontarska A, Jachalska A, Rzepecki P, Subocz E, Boguradzki P, Charlinski G, Dzierzak-Mietla M, Wisniewska-Piaty K, Swistek W, Kopacz A, Blajer-Olszewska B, Swiderska A, Dmoszynska A. Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group. Leuk Res 2014; 38:788-94. [PMID: 24862794 DOI: 10.1016/j.leukres.2014.04.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Revised: 04/19/2014] [Accepted: 04/24/2014] [Indexed: 01/10/2023]
Abstract
The observational study was aimed at evaluating response, survival and toxicity of bortezomib-based, case-adjusted regimens in real-life therapy of 708 relapsed/refractory MM patients. Bortezomib was combined with anthracyclines, steroids, thalidomide, alkylators or given in monotherapy. The ORR was 67.9% for refractory and 69.9% for relapsed MM. The median PFS was 14 months and OS 57 months. Patients responding to the therapy had the probability of a 4-year OS at 67.0%. No toxicity was noted in 33.1% of patients. Severe events (grade 3/4) were reported in 35.9% of patients: neurotoxicity (16.7%), neutropenia (9.2%), thrombocytopenia (8.5%), and infections (6.5%). Bortezomib-based, case-adjusted regimens are in real-life practice effective in salvage therapy offering reliable survival with acceptable toxicity for relapsed/refractory MM patients.
Collapse
Affiliation(s)
- Adam Walter-Croneck
- Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland.
| | - Norbert Grzasko
- Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland
| | - Maria Soroka-Wojtaszko
- Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland
| | - Artur Jurczyszyn
- Department of Haematology, Collegium Medicum, Jagiellonian University, Cracow, Poland
| | - Tigran Torosian
- Department of Haematology, Oncology and Internal Medicine, Medical University of Warsaw, Poland
| | | | - Adam Nowicki
- Department of Haematology Medical University of Poznan, Poland
| | | | - Ewa Lech-Maranda
- Centre of Postgraduate Medical Education, Warsaw, Poland; Institute of Hematology and Transfusion Medicine, Warsaw, Poland
| | - Elzbieta Madro
- Institute of Hematology and Transfusion Medicine, Warsaw, Poland
| | - Patrycja Zielinska
- Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland
| | | | - Danuta Blonska
- Department of Haematology Medical University of Bydgoszcz, Poland
| | - Lidia Usnarska-Zubkiewicz
- Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland
| | - Stanislaw Potoczek
- Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland
| | | | | | | | | | | | | | | | - Malwina Rybicka
- Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland
| | | | - Anna Jachalska
- Department of Haematology Medical University of Bydgoszcz, Poland
| | - Piotr Rzepecki
- Department of Haematology, Military Institute of Medicine in Warsaw, Poland
| | - Edyta Subocz
- Department of Haematology, Military Institute of Medicine in Warsaw, Poland
| | - Piotr Boguradzki
- Department of Haematology, Oncology and Internal Medicine, Medical University of Warsaw, Poland
| | - Grzegorz Charlinski
- Department of Haematology, Oncology and Internal Medicine, Medical University of Warsaw, Poland
| | - Monika Dzierzak-Mietla
- Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland
| | - Katarzyna Wisniewska-Piaty
- Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland
| | - Wojciech Swistek
- Department of Haematology Medical University of Bydgoszcz, Poland
| | | | | | | | - Anna Dmoszynska
- Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland
| |
Collapse
|
17
|
Chiang SY, Burli RW, Benz CC, Gawron L, Scott GK, Dervan PB, Beerman TA. Targeting the ets binding site of the HER2/neu promoter with pyrrole-imidazole polyamides. J Biol Chem 2000; 275:24246-54. [PMID: 10818092 DOI: 10.1074/jbc.m000820200] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Three DNA binding polyamides () were synthesized that bind with high affinity (K(a) = 8.7. 10(9) m(-1) to 1.4. 10(10) m(-1)) to two 7-base pair sequences overlapping the Ets DNA binding site (EBS; GAGGAA) within the regulatory region of the HER2/neu proximal promoter. As measured by electrophoretic mobility shift assay, polyamides binding to flanking elements upstream () or downstream (2 and 3) of the EBS were one to two orders of magnitude more effective than the natural product distamycin at inhibiting formation of complexes between the purified EBS protein, epithelial restricted with serine box (ESX), and the HER2/neu promoter probe. One polyamide, 2, completely blocked Ets-DNA complex formation at 10 nm ligand concentration, whereas formation of activator protein-2-DNA complexes was unaffected at the activator protein-2 binding site immediately upstream of the HER2/neu EBS, even at 100 nm ligand concentration. At equilibrium, polyamide 1 was equally effective at inhibiting Ets/DNA binding when added before or after in vitro formation of protein-promoter complexes, demonstrating its utility to disrupt endogenous Ets-mediated HER2/neu preinitiation complexes. Polyamide 2, the most potent inhibitor of Ets-DNA complex formation by electrophoretic mobility shift assay, was also the most effective inhibitor of HER2/neu promoter-driven transcription measured in a cell-free system using nuclear extract from an ESX- and HER2/neu-overexpressing human breast cancer cell line, SKBR-3.
Collapse
Affiliation(s)
- S Y Chiang
- Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
| | | | | | | | | | | | | |
Collapse
|
18
|
Chiang SY, Bruice TC, Azizkhan JC, Gawron L, Beerman TA. Targeting E2F1-DNA complexes with microgonotropen DNA binding agents. Proc Natl Acad Sci U S A 1997; 94:2811-6. [PMID: 9096302 PMCID: PMC20278 DOI: 10.1073/pnas.94.7.2811] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/02/1997] [Indexed: 02/04/2023] Open
Abstract
Microgonotropen (MGT) DNA binding drugs, which consist of an A+T-selective DNA minor groove binding tripyrrole peptide and polyamine chains attached to a central pyrrole that extend drug contact into the DNA major groove, were found to be extraordinarily effective inhibitors of E2 factor 1 (E2F1) association with its DNA promoter element (5'-TTTCGCGCCAAA). The most active of these drugs, MGT-6a, was three orders of magnitude more effective than distamycin and inhibited complexes between E2F1 and the dihydrofolate reductase promoter by 50% at 0.00085 microM. A relationship was found between the measured equilibrium constants for binding of MGTs to the A+T region of d(GGCGA3T3GGC)/d(CCGCT3A3CCG) and their inhibition of complex formation between E2F1 and the DNA promoter element. A representative of the potent MGT inhibitors was significantly more active on inhibition of E2F1-DNA complex formation compared with disruption of a preexisting complex.
Collapse
Affiliation(s)
- S Y Chiang
- Experimental Therapeutics Department, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | | | | | | | | |
Collapse
|
19
|
Skubiszewska T, Mrzygłód S, Warczyński A, Gawron L. [Comparison of the results of simultaneous trabeculectomy and cataract extraction with microscopic evaluation]. Klin Oczna 1990; 92:223-5. [PMID: 2090866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The dependence of hydrodynamics on the topography of trabeculectomy performed simultaneously with cataract extraction was checked in 35 eyes with cataract and glaucoma. The eye was opened by a three-surface incision with a broad scleral flap. The specimen were examined in a microscope. In 21 eyes the whole trabeculum together with Schlemm's canal were excised, in 12 eyes the anterior band. In the specimen from 2 eyes no elements of the trabeculum could be found. The dependence of the regulation of the IOP on the geography of the trabeculectomy was established. Accepting the filtering mechanism of the trabeculectomy one may assume that the applied method of incision promotes the formation of the outflow++ ways of the aqueous in a high percentage of cases.
Collapse
Affiliation(s)
- T Skubiszewska
- Kliniki Okulistycznej Centralnego Szpitala Klinicznego, WAM w Warszawie, Poland
| | | | | | | |
Collapse
|